Polaryx Therapeutics, Inc. (PLYX)
NASDAQ: PLYX · Real-Time Price · USD
5.63
+0.56 (11.05%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Polaryx Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Selling, General & Admin
1.561.541.01
Research & Development
6.272.812.77
Operating Expenses
7.824.353.78
Operating Income
-7.82-4.35-3.78
Other Non Operating Income (Expenses)
-1.16-260
Pretax Income
-8.99-30.36-3.78
Net Income
-8.99-30.36-3.78
Net Income to Common
-8.99-30.36-3.78
Shares Outstanding (Basic)
453411
Shares Outstanding (Diluted)
453411
Shares Change (YoY)
32.81%219.94%-
EPS (Basic)
-0.20-0.89-0.35
EPS (Diluted)
-0.20-0.89-0.35
EBIT
-7.82-4.35-3.78
Source: S&P Capital IQ. Standard template. Financial Sources.